Financials

	2023	2024
Net sales	450K 391K 365K 335K 631K 42.86M 643K 4.3M 1.68M 21.37M 1.69M 1.65M 70.49M	536K 466K 435K 400K 753K 51.12M 766K 5.13M 2.01M 25.49M 2.01M 1.97M 84.09M
Net income	-4.62M -4.01M -3.75M -3.44M -6.49M -440M -6.6M -44.19M -17.31M -220M -17.35M -16.97M -724M	-5.02M -4.36M -4.07M -3.74M -7.05M -478M -7.17M -47.99M -18.8M -238M -18.84M -18.42M -786M
Net Debt	-3.16M -2.74M -2.56M -2.35M -4.43M -301M -4.51M -30.21M -11.83M -150M -11.86M -11.6M -495M	-2.14M -1.86M -1.73M -1.59M -3M -204M -3.05M -20.45M -8.01M -102M -8.03M -7.85M -335M

* Estimated data More financial data

Company Profile

Lipella Pharmaceuticals Inc. was a clinical-stage biotechnology company. The Company is no longer in operation and does not have any business activities.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 15:56:35 2026-06-03 EDT			5-day change	1st Jan Change
0.0800 ^USD	-21.57%		+144.65%	-55.56%

07-14	An undisclosed buyer agreed to acquire Substantially all of the assets of Lipella Pharmaceuticals Inc from Lipella Pharmaceuticals Inc. for $3.4 million.	CI
03-30	Lipella Pharmaceuticals Inc. files voluntary petitions for relief under Chapter 11	RE

Market Cap	832K 723K 675K 620K 1.17M 79.28M 1.19M 7.96M 3.12M 39.54M 3.12M 3.06M 130M	P/E 2023	-1.32x	P/E 2024	-0.64x
Enterprise Value	-1.31M -1.13M -1.06M -972K -1.83M -124M -1.87M -12.49M -4.89M -62.05M -4.9M -4.8M -205M	EV / Sales 2023	6.14x	EV / Sales 2024	2.89x
Free-Float	93.69%	Yield 2023 *	-	Yield 2024	-

07-14	An undisclosed buyer agreed to acquire Substantially all of the assets of Lipella Pharmaceuticals Inc from Lipella Pharmaceuticals Inc. for $3.4 million.	CI
03-30	Lipella Pharmaceuticals Inc. files voluntary petitions for relief under Chapter 11	RE
03-30	Lipella Pharmaceuticals Inc. Filed for Bankruptcy	CI
02-04	Lipella Pharmaceuticals Inc. Announces Resignation of Director Lori A. Birder, Effective February 3, 2026	CI
11-14	Lipella Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-09	Lipella Pharmaceuticals Inc. Announces Retirement of Michael Chancellor as Chief Medical Officer and Member of the Board of Directors, Effective December 4, 2025	CI
25-09-18	Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus	CI
25-09-18	Lipella Pharmaceuticals announces positive final results from Phase 2a study of LP-10 in oral lichen planus	RE
25-08-14	Lipella Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-06-23	Lipella Pharmaceuticals Inc.(NasdaqCM:LIPO) dropped from S&P TMI Index	CI
25-06-18	Lipella Pharmaceuticals Inc.(OTCPK:LIPO) dropped from NASDAQ Composite Index	CI
25-06-04	Lipella Pharmaceuticals Inc. Re-Signs Manufacturing Collaboration Agreement with Cook MyoSite Inc. to Support LP-310 Clinical Development	CI
25-05-15	Lipella Pharmaceuticals to Present Phase 2A Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting	CI

25-02-11	Top Midday Gainers	MT
24-04-09	Maxim Initiates Lipella Pharmaceuticals at Buy Rating With $2 Price Target	MT

Lipella Pharmaceuticals Inc. Stock

Stocks

LIPO

US53630L2097

Biotechnology & Medical Research

Valuation: Lipella Pharmaceuticals Inc.

Chart: Lipella Pharmaceuticals Inc.

Latest news : Lipella Pharmaceuticals Inc.

Analysts' recommendations: Lipella Pharmaceuticals Inc.

Press Releases: Lipella Pharmaceuticals Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Lipella Pharmaceuticals Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Income Statement and Estimates

Quarterly revenue - Rate of surprise

25-09-18	Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus	AQ
25-09-15	Lipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen Planus	PR
25-06-25	Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting	AQ
25-06-20	Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market	AQ
25-06-17	Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology	AQ

1 day	-21.57%
1 week	+144.65%
Current month	+144.65%
1 month	-38.46%
3 months	+282.78%
6 months	-61.92%
Current year	-55.56%

1 month	0.03	0.12
Current year	0.02	0.32
1 year	0.02	0.7
3 years	0.02	21.68
5 years	0.02	61.76
10 years	0.02	61.76

Manager	Title	Age	Since
Jonathan Kaufman CEO	Chief Executive Officer	60	2004-12-31
Douglas Johnston DFI	Director of Finance/CFO	42	2021-09-30
Janet Okonski CTO	Chief Tech/Sci/R&D Officer	-	2021-07-31

Director	Title	Age	Since
Jonathan Kaufman CHM	Chairman	60	2004-12-31
Byong Kim BRD	Director/Board Member	55	2022-02-28
Ryan Pruchnic BRD	Director/Board Member	53	2021-08-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
4/3/25	Jonathan Kaufman	Others	Chief Executive Officer	695,776	27.2981%
3/13/25	Jonathan Kaufman	Others	Chief Executive Officer	14,386	0.5644%
3/10/25	Jonathan Kaufman	Others	Chief Executive Officer	28,924	1.1348%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LIPELLA PHARMACEUTICALS INC.	-21.57%	+144.65%	-88.73%	-99.48%	151K
WUXI APPTEC CO., LTD.	+0.05%	+3.08%	+38.17%	+66.77%	56.7B
ARGENX SE	+0.33%	-6.24%	+23.18%	+61.71%	51.97B
BIONTECH SE	+1.84%	+1.27%	-14.06%	-13.50%	23.33B
INSMED INCORPORATED	-0.15%	-6.00%	-9.42%	+344.47%	21.34B
GENMAB A/S	+0.91%	-2.31%	+31.82%	-26.35%	17.44B
PHARMAESSENTIA CORPORATION	+9.91%	-2.51%	+188.84%	+326.19%	14.77B
EXELIXIS, INC.	+3.83%	-1.34%	+47.77%	+165.22%	13.84B
ARROWHEAD PHARMACEUTICALS, INC.	+1.61%	+0.56%	+439.92%	+166.12%	12.12B
MADRIGAL PHARMACEUTICALS, INC.	+3.14%	-12.56%	+59.51%	+149.39%	11.14B
Average	-0.02%	-2.09%	+71.70%	+114.05%	22.26B
Weighted average by Cap.	+1.45%	-1.95%	+57.66%	+109.37%